Levodropropizine Elc (Levodropropizine)

Levodropropizine acts peripherally on sensory C‑fibers in the airway lining. By inhibiting the activation of these fibers, it diminishes the afferent signals that trigger the cough reflex, leading to a reduction in cough frequency without affecting the central nervous system.

The appropriate dose of Levodropropizine Elc is determined by the prescribing healthcare professional based on the patient’s age, weight, and clinical condition. Patients should follow the prescriber’s instructions and the product label for correct usage.

Safety data for levodropropizine in pregnancy and lactation are limited. Healthcare providers should evaluate the risk‑benefit ratio before prescribing it to pregnant or nursing mothers, and it should only be used if clearly needed.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike centrally acting opioids such as codeine, levodropropizine works peripherally and does not cause sedation or dependence. It is generally better tolerated for patients who need cough relief without the central nervous system effects associated with opioid antitussives.

Levodropropizine Elc should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually as a tablet or liquid preparation, as directed by the prescriber. It should be swallowed with water and can be taken with or without food, unless the label advises otherwise.

Serious adverse reactions, although rare, include allergic responses such as rash, swelling, or anaphylaxis, and potential liver enzyme elevations. Patients should seek immediate medical attention if they experience signs of a severe allergic reaction or unexplained liver problems.

Individuals with known hypersensitivity to levodropropizine or any excipients in the formulation should avoid the product. Caution is also advised for patients with severe renal or hepatic impairment, and it should not be given to infants under two years of age without medical supervision.